The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A good idea to tweet it or whatever you do to other jurnos Mr sky the lady from telegraph who inanaco has probably scared off lol etc
Couple of things about Twitter - 1) Scancell have tweeted out the article. 2) the twitter account linked to the article page is still suspended, 3) if anyone can get to MARCUS on Twitter, please let them know that putting ANY character in front the @ACOUNTNAME will mean everyone can see his tweets, otherwise it is limited to the named account and those found via a search. He's not following me, so I cannot DM that info.
I think Scancell has as many likes and RTs on their tweet as I've every seen. I'm not sure if the article indicates that they are cultivating journos or not. I'm expecting a round of other publications quoting from it over the next week or so.
ATB all!
I'm sure this has been posted here before and this PhD is being sponsored by Scancell. Maybe they already have needle-free delivery systems and this PhD is to improve on them.
https://www.findaphd.com/phds/project/development-of-an-intradermal-or-inhaled-dna-vaccine-for-covid-19-and-beyond/?p127093
"Intradermal and inhaled delivery of nucleic acid vaccines could be clinically effective, safe and globally-deployable against multiple complex diseases. This project will aim to combine physical and peptide-based delivery systems to enhance the efficacy and application of such technologies to the COVID-19 vaccine (‘Covidity’) presently under-development by our consortium (funded by Innovate-UK). This PhD will formulate and test combined systems for skin and lung-focused vaccine delivery in ex vivo tissue models, then move to rodent models, examining virus neutralisation, T cell responses and protection in virally challenged animals. The platform technology optimised and demonstrated will have wide ranging impact on future applications of nucleic acid vaccine approaches (including DNA, mRNA and oligo-based methods). The PhD will also directly aid attempts to translate antibody and peptide-engineering knowhow to generate a rapidly deployable and safe immunisation system for multiple complex diseases."
GF
Difficult to say. I suspect that there most likely has been some iteration of what Nottingham have already published on. But entirely unsure.
We should find out in due course whether it is entirely new and how it delivers the vaccine.
Burble
Quick question. Do you think sclp could have developed their own needle free 'Mechanism" and as such could the sclp spv be specially for this yet un-patented protected product? I'm far from clear how sclp intend to push on with trials when there is a clear lack of understanding with investors and the market how they intend to administer their vaccine.
Any thoughts?
ATB
2CV
Needle-free secrecy may be that it’s been submitted for patent protection. If anything is in the public domain, then you struggle to patent it. It’s a PITA when it comes to scientific publishing because you want to publish papers but can’t because that would invalidate your patent application. It’s also a nightmare when it comes to presenting at conferences as a PhD student/post-doc/academic because the same rules apply.
Possibly it needing a 3rd party tie in? I posted about pharmajet a device the Indian DNA vax uses...
Though you're right they are tantalisingly keeping us in the dark about it lol
Very positive and supportive article, thanks Bill.
I'm intrigued as to why so much secrecy surrounds the needle-free applications ( "the company declined to comment" ) and can't fathom a reason for it. Not that it really matters, and in any case the secret should be out very soon when the first doses are given.
https://www.william-reed.com
Is the parent company the article sits under.
Nice one Bill!
I'd reckon Sally is also behind these quotes....
Scancell in the race... seatbelts on?
'Ultimately, It is likely that a repertoire of C19 vaccines will be required to offer widespread protection. Different vaccine formulations will ensure vaccination is safe and effective for all members of society, infants, the elderly and people with weak immune systems . The requirement for BILLIONS of vaccine doses worldwide also suggests there will need to be multiple vaccines in circulation with different manufacturing processes to minimise shortages in raw materials
Amen ... and here is to the most effective affordable and scalable ones :)
Basically saying adenoviral vaxs nah... mRNA ones nah..... here comes multi Antigen DNA ones :)))) game changer written all over it
Compared to the viral vector vaccines, scancell notes the hesitancy about using those over blood clotting fears in these types; while noting that anti-vector immunity could emerge as a problem.
'Multiple boosting for these virally-vectored vaccines will be limited by progressive boosting of anti-vector immunity and new variant adenovirus-based vaccines may not be feasible due to pre existing vector immunity that is likely to abrogate responses against any new insertion '
Also did not know this!
mRNA can only incorporated a single antigen including a second antigen would require the development of a second separate mRNA vaccine, Covidity can incorporate multiple antigens in one vaccine....
DNA vaxs cheap easy to manufacture and store... and safe....
SCIENCE it go scancell... super bullish piece that :)
Great find, Bill!!
And needle-free injections appear to be confirmed for the South African trial!
It's all about Covidity with scancell quotes :) they had a Sally quote in their previous article... so obs a bit of a connection there between this publication and scancell.... As for how highly regarded a publication... can't say I know it lol...
Seconded, great article @billbrown.
@crumbs, I would say the article is about Scancell primarily and using Scancell as a springboard to discuss DNA vaccines?
I take it biopharma reporter are fairly well recognised?
A brilliant article! With plenty of scancell commentary in it.... hopefully more of this kind of coverage to come
https://www.biopharma-reporter.com/Article/2021/08/02/Could-DNA-based-COVID-19-vaccine-offer-variant-busting-booster-shot
Could DNA-based COVID-19 vaccine offer variant-busting booster shot?
02-Aug-2021 By Rachel Arthur
With Scancell taking its DNA-based COVID-19 vaccine tech into clinical trials this year, it is already focusing its attention on the tech’s potential to be used as a needle-free booster shot to address Variants of Concern.